Hepatitis B Virus Status and Clinical Outcomes in IgA Nephropathy

Overview

Journal Kidney Int Rep

Publisher Elsevier

Specialty Nephrology

Date 2024 May 20

PMID 38765575

Authors

Mei-Zhu Gao

Lin-Lin Xu

Yang Li

Xin Wang

Pei Chen

Su-Fang Shi

Li-Jun Liu

Ji-cheng Lv

Fu-Yuan Hong

Hong Zhang

Xu-Jie Zhou

Affiliations

Soon will be listed here.

Abstract

Introduction: Immunoglobulin A nephropathy (IgAN) has been reported to coexist with hepatitis B virus (HBV) infection. Despite the clinical significance of this association, there is a lack of comprehensive research investigating the impact of various common conditions following HBV infection and the potential influence of anti-HBV therapy on the progression of IgAN.

Methods: We investigated 3 distinct states of HBV infection, including chronic HBV infection, resolved HBV infection, and the deposition of hepatitis B antigens in renal tissue, in a follow-up database of 1961 patients with IgAN. IgAN progression was defined as a loss of estimated glomerular filtration rate (eGFR) >40%. Multivariable cause-specific hazards models to analyze the relationship between HBV states and IgAN progression.

Results: Chronic HBV infection was identified as an independent risk factor for IgAN progression, supported by both prematching analysis (hazard ratio [HR], 1.61; 95% confidence interval [CI], 1.06-2.44; = 0.024) and propensity-score matching analysis (HR, 1.74; 95% CI 1.28-2.37; < 0.001). Conversely, resolved HBV infection showed no significant association with IgAN progression (HR, 1.01; 95% CI 0.67-1.52; = 0.969). Moreover, the presence of HBV deposition in the kidneys and the utilization of anti-HBV therapy did not appear to be significant risk factors for renal outcomes ( > 0.05).

Conclusion: Chronic HBV infection is an independent risk factor for IgAN progression, whereas resolved HBV infection is not. In patients with IgAN, management of concurrent chronic HBV infection should be enhanced. The presence of HBV deposition in the kidneys and the use of anti-HBV medications do not impact the kidney disease progression in patients with IgAN with concurrent HBV infection.

Citing Articles

The neutrophil-lymphocyte ratio as a risk factor for all-cause mortality among individuals with resolved HBV infection: evidence from the NHANES 1999-2018.

Qiu C, Yu C, Yang L, Liu S, Zhang Q, Jia S Front Public Health. 2025; 12:1493439.

PMID: 39882122 PMC: 11775152. DOI: 10.3389/fpubh.2024.1493439.

The relationship between HBV antigens deposition in kidneys and renal prognosis in IgA nephropathy patients infected with HBV.

Guo Y, Li S, Wei J, Luo M, Liu H Ren Fail. 2024; 46(2):2417737.

PMID: 39555693 PMC: 11574957. DOI: 10.1080/0886022X.2024.2417737.

References

Baidya A, Khatun M, Mondal R, Ghosh S, Chakraborty B, Mallik S . Hepatitis B virus suppresses complement C9 synthesis by limiting the availability of transcription factor USF-1 and inhibits formation of membrane attack complex: implications in disease pathogenesis. J Biomed Sci. 2022; 29(1):97. PMC: 9664717. DOI: 10.1186/s12929-022-00876-1. View

Roos A, Rastaldi M, Calvaresi N, Oortwijn B, Schlagwein N, van Gijlswijk-Janssen D . Glomerular activation of the lectin pathway of complement in IgA nephropathy is associated with more severe renal disease. J Am Soc Nephrol. 2006; 17(6):1724-34. DOI: 10.1681/ASN.2005090923. View

Lau G, Yu M, Wong G, Thompson A, Ghazinian H, Hou J . APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int. 2021; 15(5):1031-1048. PMC: 8382940. DOI: 10.1007/s12072-021-10239-x. View

Long J, Rutledge S, Sise M . Autoimmune Kidney Diseases Associated with Chronic Viral Infections. Rheum Dis Clin North Am. 2018; 44(4):675-698. DOI: 10.1016/j.rdc.2018.06.006. View

Lai K, Lai F, Tam J . IgA nephropathy associated with chronic hepatitis B virus infection in adults: the pathogenetic role of HBsAG. J Pathol. 1989; 157(4):321-7. DOI: 10.1002/path.1711570409. View

Kong X, Ma Y, Chen J, Luo Q, Yu X, Li Y . Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating glomerular filtration rate in the Chinese population. Nephrol Dial Transplant. 2012; 28(3):641-51. DOI: 10.1093/ndt/gfs491. View

Wang N, Wu Z, Zhang Y, Liao L . Existence and significance of hepatitis B virus DNA in kidneys of IgA nephropathy. World J Gastroenterol. 2005; 11(5):712-6. PMC: 4250745. DOI: 10.3748/wjg.v11.i5.712. View

Hsu Y, Huang D, Nguyen M . Global burden of hepatitis B virus: current status, missed opportunities and a call for action. Nat Rev Gastroenterol Hepatol. 2023; 20(8):524-537. DOI: 10.1038/s41575-023-00760-9. View

Chen Y, Li C, Tsai S, Chen Y . Nationwide cohort study suggests that nucleos(t)ide analogue therapy decreases dialysis risk in Taiwanese chronic kidney disease patients acquiring hepatitis B virus infection. World J Gastroenterol. 2018; 24(8):917-928. PMC: 5829155. DOI: 10.3748/wjg.v24.i8.917. View

10.

Trimarchi H, Barratt J, Cattran D, Cook H, Coppo R, Haas M . Oxford Classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group. Kidney Int. 2017; 91(5):1014-1021. DOI: 10.1016/j.kint.2017.02.003. View

11.

Zhu C, Song H, Xu F, Yi W, Liu F, Liu X . Hepatitis B virus inhibits the expression of complement C3 and C4, and . Oncol Lett. 2018; 15(5):7459-7463. PMC: 5920570. DOI: 10.3892/ol.2018.8223. View

12.

Sallustio F, Picerno A, Cimmarusti M, Montenegro F, Curci C, De Palma G . Elevated levels of IL-6 in IgA nephropathy patients are induced by an epigenetically driven mechanism modulated by viral and bacterial RNA. Eur J Intern Med. 2023; 118:108-117. DOI: 10.1016/j.ejim.2023.07.045. View

13.

Pattrapornpisut P, Avila-Casado C, Reich H . IgA Nephropathy: Core Curriculum 2021. Am J Kidney Dis. 2021; 78(3):429-441. DOI: 10.1053/j.ajkd.2021.01.024. View

14.

Saha M, Julian B, Novak J, Rizk D . Secondary IgA nephropathy. Kidney Int. 2018; 94(4):674-681. PMC: 6981247. DOI: 10.1016/j.kint.2018.02.030. View

15.

Sallustio F, Picerno A, Montenegro F, Cimmarusti M, Di Leo V, Gesualdo L . The Human Virome and Its Crosslink with Glomerulonephritis and IgA Nephropathy. Int J Mol Sci. 2023; 24(4). PMC: 9964221. DOI: 10.3390/ijms24043897. View

16.

Maillard N, Wyatt R, Julian B, Kiryluk K, Gharavi A, Fremeaux-Bacchi V . Current Understanding of the Role of Complement in IgA Nephropathy. J Am Soc Nephrol. 2015; 26(7):1503-12. PMC: 4483595. DOI: 10.1681/ASN.2014101000. View

17.

Shi Y, Zheng M . Hepatitis B virus persistence and reactivation. BMJ. 2020; 370:m2200. DOI: 10.1136/bmj.m2200. View

18.

He J, Zhou X, Lv J, Zhang H . Perspectives on how mucosal immune responses, infections and gut microbiome shape IgA nephropathy and future therapies. Theranostics. 2020; 10(25):11462-11478. PMC: 7545987. DOI: 10.7150/thno.49778. View

19.

Wang N, Wu Z, Zhang Y, Guo M, Liao L . Role of hepatitis B virus infection in pathogenesis of IgA nephropathy. World J Gastroenterol. 2003; 9(9):2004-8. PMC: 4656662. DOI: 10.3748/wjg.v9.i9.2004. View

20.

Etienne S, Vosbeck J, Bernsmeier C, Osthoff M . Prevention of Hepatitis B Reactivation in Patients Receiving Immunosuppressive Therapy: a Case Series and Appraisal of Society Guidelines. J Gen Intern Med. 2022; 38(2):490-501. PMC: 9905451. DOI: 10.1007/s11606-022-07806-9. View